Diabétologie [Are pioglitazone and fenofibrate effective for the prevention of cardiovascular disease in type 2 diabetes?]

Détails

ID Serval
serval:BIB_7B2DFDA51497
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Diabétologie [Are pioglitazone and fenofibrate effective for the prevention of cardiovascular disease in type 2 diabetes?]
Périodique
Revue Médicale Suisse
Auteur⸱e⸱s
Ruiz J.
ISSN
1660-9379
Statut éditorial
Publié
Date de publication
01/2006
Volume
2
Numéro
48
Pages
116-118
Langue
français
Résumé
This year, two prospective randomized studies aimed at the reduction of composite cardiovascular endpoints in type 2 diabetic patients. The PROactive study estimated the impact of pioglitazone in the secondary prevention. The significant reduction of the primary composite endpoint was not obtained: reduction of the relative risk (RR) of 10 % (p= 0.095). However, the secondary composite endpoint was significantly reduced RR 16 % (p = 0.027). The FIELD study also had the same objectives. The primary composite endpoint was not significantly reduced in spite of a RR of 11% while the reduction of RR was significant for the secondary composite endpoint (p = 0.035). These studies reveal the difficulties and the complexity of the secondary prevention of atherosclerosis for patients already treated with effective molecules.
Mots-clé
Antilipemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Procetofen, Randomized Controlled Trials as Topic, Thiazolidinediones
Pubmed
Création de la notice
03/03/2008 15:15
Dernière modification de la notice
20/08/2019 14:37
Données d'usage